Dr. Reddy's Laboratories Ltd. (DRREDDY.NS)
-NSE 2,066.10 
14.65(0.71%) 24 May 17:59 SGT
| Prev Close: | 2,051.45 |
|---|
| Open: | 2,068.00 |
|---|
| Bid: | N/A |
|---|
| Ask: | 2,066.10 |
|---|
| 1y Target Est: | 2,223.03 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2,053.45 - 2,071.05 |
|---|
| 52wk Range: | 1,526.40 - 2,152.00 |
|---|
| Volume: | 342,628 |
|---|
| Avg Vol (3m): | 318,081 |
|---|
| Market Cap: | 350.91B |
|---|
| P/E (ttm): | 20.99 |
|---|
| EPS (ttm): | 98.44 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in INR.
External Headlines
- Fresenius Hits Dr. Reddy's With Diprivan IP Suit@ Law360 (subscription)(Sat, 25 May)
- Sensex trades up 75 points; Sun Pharma, Dr Reddy's lead@ Myiris.com(Wed, 22 May)
- Dr Reddy's welcomes new pharma pricing policy@ Business Standard(Sat, 18 May)
- Dr Reddy's says 'have factored in the impact'@ Hindu Business Line(Fri, 17 May)
- Dr Reddy's welcomes the new pharmaceutical pricing policy@ Business Standard(Fri, 17 May)
- DR. REDDY'S LABORATORIES LIMITED : Dr. Reddy's Q4 & FY13 Financial ... - 4@ traders (press release)(Thu, 16 May)
- Lupin gains No 2 slot overtaking Dr Reddy's@ Business Standard(Thu, 16 May)
- Lupin gains No 2 slot overtaking Dr Reddy's@ Business Standard(Thu, 16 May)
- Dr Reddy's Lab extends gains on strong Q4 earnings@ Business Standard(Thu, 16 May)
- Dr. Reddy's Laboratories Limited - Inline performance, outlook no longer ...@ Equity Bulls(Thu, 16 May)
Headlines
- BSE Sensex falls from near 2-1/2 year high; banks hitReuters(Mon, 20 May)
- Drugmakers fall on government price control policyReuters(Fri, 17 May)
- Sensex gains; inflation springs downside surpriseReuters(Tue, 14 May)
- Dr Reddy's hits all-time high ahead of Jan-March earningsReuters(Mon, 13 May)
- Weekahead - Shares to watch inflation, foreign flowsReuters(Fri, 10 May)
- Top generic drugmakers look to US as patents endReuters(Wed, 8 May)
- Nomura "overweight" on rate-cyclicals, defensivesReuters(Thu, 2 May)
- Pharma stocks at new highs on hopes of strong domestic growthReuters(Thu, 25 Apr)
- BSE Sensex gains for fourth day; rate-sensitives upReuters(Thu, 25 Apr)
- Defensives gain after Infosys slumpsReuters(Fri, 12 Apr)
Key Statistics
| Forward P/E (1 yr): | 16.43 |
|---|
| P/S (ttm): | 3.00 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 110.06 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 31.83 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.05 |
|---|
Business Summary
Dr. Reddys Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products.
View More